CRNX CSO granted 47K options and 30K RSUs

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. reported that Chief Scientific Officer Stephen F. Betz

He received a stock option covering 47,000 shares of common stock, vesting in forty-eight equal monthly installments starting from a vesting commencement date of February 23, 2026. He also received 30,000 restricted stock units, each representing a right to receive one share of common stock, with 25% vesting annually beginning on March 1, 2027. Both awards were reported at a price per share of $0.00, reflecting grants rather than open‑market purchases.

Insider Trade Summary

Grant/Award: 77,000 shares

Grant/Award 2 txns

Insider Betz Stephen F.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	47,000	$0.00	$0.00
Grant/Award	Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 47,000 contracts (Direct); Common Stock — 147,713 shares (Direct)

Footnotes (2)

F1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
F2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CRNX Chief Scientific Officer Stephen F. Betz report?

Stephen F. Betz reported receiving equity awards from Crinetics Pharmaceuticals, Inc. He acquired a stock option for 47,000 shares of common stock and 30,000 restricted stock units. Both awards were granted at a price per share of $0.00 as non-cash equity compensation.

How many stock options did the CRNX Chief Scientific Officer receive in this Form 4?

The Chief Scientific Officer received a stock option covering 47,000 shares of Crinetics Pharmaceuticals common stock. According to the filing, this option vests in forty-eight equal monthly installments starting from the vesting commencement date of February 23, 2026, subject to continued service conditions.

What are the vesting terms for Stephen F. Betz’s CRNX restricted stock units?

The filing states that the transaction involves 30,000 restricted stock units. These RSUs represent rights to receive common shares, with 25% of the units vesting annually beginning on March 1, 2027, which spreads vesting over four years, assuming continued employment or satisfaction of applicable conditions.

At what price were the CRNX equity awards to Stephen F. Betz reported?

Both the stock option and the restricted stock unit awards to Stephen F. Betz were reported with a transaction price per share of $0.00. This indicates they were granted by the company as equity awards rather than purchased on the open market for cash consideration.

How many CRNX common shares does Stephen F. Betz hold after this Form 4 transaction?

Following the restricted stock unit grant, Stephen F. Betz is reported as directly owning 147,713 shares of Crinetics Pharmaceuticals common stock. This total reflects his common stock holdings after the acquisition reported in the Form 4, according to the ownership figure disclosed.

When do the CRNX stock options granted to the Chief Scientific Officer become exercisable?

The stock options granted to the Chief Scientific Officer vest and become exercisable over time. The filing explains they vest in forty-eight successive equal monthly installments, measured from a vesting commencement date of February 23, 2026, creating a four-year monthly vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/25/2026 - 04:34 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Betz Stephen F.

(Last)

(First)

(Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/23/2026		A		30,000	A	$0⁽¹⁾	147,713	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$43.79	02/23/2026		A		47,000		⁽²⁾	02/23/2036	Common Stock	47,000	$0	47,000	D

Explanation of Responses:

1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR